Dr. Robson on Differences Between Biosimilars and Biologics in Oncology

Mark E. Robson, MD
Published: Tuesday, Nov 19, 2019



Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the importance of educational efforts aimed at understanding the differences between biosimilars and biologics in oncology.
 
Educational efforts regarding the development and approval process for biosimilars could help reduce the skepticism that is associated with these agents, says Robson. 

Regulatory pathway differences between biosimilars and originator compounds are often misunderstood. Explanation of the biosimilar approval process could help clarify these differences and shed light on the current criteria that are used to demonstrate similarity between these agents, concludes Robson.
SELECTED
LANGUAGE


Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the importance of educational efforts aimed at understanding the differences between biosimilars and biologics in oncology.
 
Educational efforts regarding the development and approval process for biosimilars could help reduce the skepticism that is associated with these agents, says Robson. 

Regulatory pathway differences between biosimilars and originator compounds are often misunderstood. Explanation of the biosimilar approval process could help clarify these differences and shed light on the current criteria that are used to demonstrate similarity between these agents, concludes Robson.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x